With a surge in new cases surpassing daily highs across the US, it is clear that the battle against COVID-19 will continue for the foreseeable future. While much of the world tries to go back to “normal”, healthcare workers on …
Trending at Lumira Ventures
HistoSonics Announces $40 Million Financing
Breakthrough medical platform offers vision of non-invasive procedures to eliminate diseased tissues and tumors MINNEAPOLIS, June 8, 2020 /PRNewswire/ — HistoSonics, developer of a non-invasive robotic platform and sonic beam therapy, announced today that it has closed $40 million in an …
UCB Acquires Engage Therapeutics: Staccato® Alprazolam – A potential Solution for Acute On-demand Seizure Management for People Living With Epilepsy
– Staccato® Alprazolam could be a potential solution for 20-30% of epilepsy patients – Initial upfront payment of US$ 125 million and further potential milestone payments of up to US$ 145 million, total potential consideration of up to US$ 270 …
Forbius Reported Safety and Initial Anti-Fibrotic Effects of First-in-Class, Selective TGF-beta Inhibitor, AVID200, in Phase 1b Systemic Sclerosis Trial at EULAR 2020
Initial results demonstrate anti-fibrotic effects of AVID200 as indicated by rapid and sustained declines in skin fibrosis. AVID200 was well-tolerated, and no dose-limiting toxicities, SAEs or adverse events greater than Grade 2 were observed. The MTD was not reached. AVID200 …
Double Bottom Line Challenge Update: Lumira Ventures gives to five additional initiatives in our communities to support those in need during the COVID-19 crisis.
Over the past several weeks, we have seen a number of provinces and states relax restrictions and open up further. Combined with the start of summer, this has caused many to ease on social distancing measures some more so than …
Lumira Ventures continues Double Bottom Line Challenge to provide support to those in need during the COVID-19 crisis.
As a leader in the Canadian life science investment community, Lumira Ventures has been closely monitoring and engaging with companies who are developing COVID-19 treatments and vaccines. While our portfolio companies and employees within have been significantly impacted by the …
Lumira Ventures continues Double Bottom Line Challenge to provide support to those in need during the COVID-19 crisis.
This week, Lumira Ventures is proud to have supported five additional high impact COVID-19 initiatives as part of our Double Bottom Line Challenge While some provinces and states are gradually beginning to reopen, unfortunately the magnitude and reach of the …
IMV Announces Proposed $22.3 Million Private Placement
DARTMOUTH, Nova Scotia–(BUSINESS WIRE)– IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company, today announced its intention to complete a private placement (the “Private Placement”) of 7,797,203 units of the Company (each, a “Unit”) at the market price of …
Lumira Ventures launches the Double Bottom Line Challenge to provide support to those in need during the COVID-19 crisis.
At Lumira Ventures, the past couple of months have been consumed with evaluating new investment opportunities, and working with our portfolio companies, governments, and the venture and healthcare ecosystems to ensure that our companies and all innovation-centric companies broadly are …
Edesa Biotech and Light chain Bioscience Sign License Agreement to Develop Treatments for COVID-19 Pneumonia and Other Disorders
TORONTO, ON / ACCESSWIRE / April 20, 2020 / Edesa Biotech, Inc. (EDSA), a clinical-stage biopharmaceutical company, today announced a strategic agreement with Light Chain Bioscience (a brand of NovImmune SA), a leading Swiss pharmaceutical development company, for an exclusive worldwide …
Aurinia Initiates rolling Submission of NDA to U.S. FDA
VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, announced today that the Company has initiated a Rolling Submission of its New Drug Application …
G1 Therapeutics Strengthens Executive Team & Board of Directors
RESEARCH TRIANGLE PARK, N.C. (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced the appointments of Jack Bailey to its Board of Directors and Soma Gupta as its Chief Commercial Officer (CCO). Related Article: G1 …
Edesa Biotech to Develop Novel Treatment for Vitiligo
TORONTO, ON / ACCESSWIRE / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today announced a collaborative research project with the National Research Council of Canada (NRC) to develop novel immunotherapies for vitiligo as well as other indications. Related Article: …
Aurinia Partners with National Kidney Foundation on Awareness Initiative
VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and autoimmune conditions, today announced new initiatives to support the lupus nephritis (LN) community …
Engage Therapeutics’ Phase 2b StATES Study Meets Primary Endpoint
SUMMIT, N.J. (GLOBE NEWSWIRE) — Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing an orally inhaled therapy designed to terminate an active epileptic seizure, today announced that its Phase 2b StATES study of Staccato® alprazolam met its primary …